Showing results (141-150 of 160) with videos related to

Sort By:
Pageof 16
Diabetes Care|January 20, 2023
Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD StudyJelle M Beernink, Frederik Persson, Niels Jongs, et al.
British Journal of Clinical Pharmacology|March 27, 2023
Initiation of glucose-lowering drugs reduces the anticoagulant effect of warfarin-But not through altered drug metabolism in patients with type 2 diabetesAnn-Cathrine Dalgård Dunvald, Flemming Nielsen, Dorte Aalund Olsen, et al.
Diabetes Care|June 29, 2021
Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD TrialFrederik Persson, Peter Rossing, Priya Vart, et al.
Scientific Reports|May 20, 2021
The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetesSuvanjaa Sivalingam, Emil List Larsen, Daniel H van Raalte, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 17, 2016
Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysisJustyna Siwy, Petra Zürbig, Angel Argiles, et al.
Clinical Kidney Journal|August 12, 2024
The validity of pathology codes for biopsy-confirmed kidney disease in the Danish National PatobankMarie Møller, Iain Bressendorff, Rikke Borg, et al.
Diabetes & Vascular Disease Research|October 20, 2022
Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosisElisabeth B Stougaard, Peter L Kristensen, Urd Kielgast, et al.
BMJ Open|April 22, 2016
Multifactorial intervention to prevent cardiovascular disease in patients with early rheumatoid arthritis: protocol for a multicentre randomised controlled trialAnnemarie Lyng Svensson, Robin Christensen, Frederik Persson, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|January 11, 2025
Protocol for a 1-year randomised, controlled, parallel group, open-label trial on the effects and feasibility of time-restricted eating in individuals with type 2 diabetes- The REStricted Eating Time in the treatment of type 2 diabetes (RESET2) trialAnne-Ditte Termannsen, Annemarie Varming, Natasja Bjerre, et al.
Pharmaceuticals (Basel, Switzerland)|September 28, 2023
Prognosis and Personalized In Silico Prediction of Treatment Efficacy in Cardiovascular and Chronic Kidney Disease: A Proof-of-Concept StudyMayra Alejandra Jaimes Campos, Iván Andújar, Felix Keller, et al.
Pageof 16